Filter Results:
(1,246)
Show Results For
- All HBS Web
(1,246)
- People (5)
- News (171)
- Research (931)
- Events (6)
- Multimedia (12)
- Faculty Publications (759)
Show Results For
- All HBS Web
(1,246)
- People (5)
- News (171)
- Research (931)
- Events (6)
- Multimedia (12)
- Faculty Publications (759)
- 06 Aug 2001
- Research & Ideas
Go Global—or No? Can You Make the Case?
Remember, we don't yet have the capability to serve the chemical and pharmaceutical industries here. There are still only 38 of us, and I estimate that building the support infrastructure we need just for domestic expansion could cost as... View Details
Keywords: by Walter Kuemmerle
- November 2006
- Case
Competitive Headaches (A): The Analgesic Wars
By: Dennis A. Yao
Addresses the problem of competing with a me-too consumer product. Focuses on Bristol-Meyers' 1975 strategy for introducing a competitor to Tylenol in the analgesic market. View Details
- November 1999
- Teaching Note
drugstore.com TN
By: Richard L. Nolan
Teaching Note for (9-300-036). View Details
- 27 May 2009
- First Look
First Look: May 27, 2009
Case 509-048 The case describes the effort of Merck, a global leader in pharmaceuticals, in making available its medicines to the poor. The challenge for the company (or for that matter, any pharmaceutical company) is how to integrate its... View Details
Keywords: Martha Lagace
- 23 Oct 2019
- News
After the Storm
class. When I started at Johnson & Johnson right after business school, I remember being the only African American female pharmaceutical sales rep in the mid-Atlantic region at that time. It’s a sad reality, but that is also why I get so... View Details
- 01 Dec 2010
- News
How to Survive Past Start-up
Cenedella tried several other ideas for job-industry companies before he came up with the idea for TheLadders. Michel spent years searching for the right business idea — even helping to start a pharmaceutical industry computer firm —... View Details
- January 2017 (Revised March 2017)
- Case
Royal DSM: From Continuous Transformation to Organic Growth
By: William W. George, Carin-Isabel Knoop and Amram Migdal
Royal DSM CEO Feike Sijbesma was pondering the challenges of shifting DSM’s global organization from the constant transformations of the past 100 years to creating organic growth. When Sijbesma took the helm as CEO in 2007, he further pushed and completed the company’s... View Details
Keywords: Organic Growth; Organizational Change; M＆A; Mergers And Acquisitions; Divestment; Business Ventures; Business Divisions; Business Growth and Maturation; Restructuring; Change; Change Management; Transformation; Transition; Engineering; Chemicals; Mining; Ethics; Values and Beliefs; Finance; Capital Markets; Financial Markets; Food; Globalization; Global Strategy; Globalized Firms and Management; Globalized Markets and Industries; Health; Nutrition; History; Leadership; Leadership Development; Leadership Style; Leading Change; Management; Business or Company Management; Growth and Development Strategy; Growth Management; Management Practices and Processes; Management Style; Organizations; Corporate Social Responsibility and Impact; Mission and Purpose; Organizational Change and Adaptation; Organizational Culture; Organizational Design; Ownership; Public Ownership; Performance; Strategy; Adaptation; Consolidation; Corporate Strategy; Value; Value Creation; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Europe; Netherlands
George, William W., Carin-Isabel Knoop, and Amram Migdal. "Royal DSM: From Continuous Transformation to Organic Growth." Harvard Business School Case 317-063, January 2017. (Revised March 2017.)
- 18 Jul 2018
- Research & Ideas
No More General Tso's? A Threat to 'Knowledge Recombination'
pharmaceutical companies, which had been flying in scientists from China and India who, like Cohly, brought knowledge of native herbs. Some pharma companies were able to earn exemptions from the H1-B limits. Choudhury and Kim used this... View Details
- 26 Jun 2000
- Research & Ideas
What’s an Internet Business Model? Ask a Health Care Professional
out how to get into a clinical trial to try an experimental drug. For their part, physicians are often befuddled by difficult cases that don't respond to traditional therapies. And pharmaceutical companies, at the same time, are anxious... View Details
- 20 Nov 2006
- Research & Ideas
Open Source Science: A New Model for Innovation
problems that were posted? A: Innovations happen at the intersection of disciplines. People have talked about that a lot and I think we're providing some systematic evidence now with this study. Another example is that a pharmaceutical... View Details
Keywords: by Martha Lagace
- 22 Apr 2014
- First Look
First Look: April 22
constraints. Download working paper: https://www.hbs.edu/faculty/Pages/download.aspx?name=14-097.pdf The Organizational and Geographic Drivers of Absorptive Capacity: An Empirical Analysis of Pharmaceutical R&D Laboratories By:... View Details
Keywords: Sean Silverthorne
- 28 Aug 2017
- Research & Ideas
Should Industry Competitors Cooperate More to Solve World Problems?
Source: Cecilie_Arcurs George Serafeim has a startling suggestion to fix the world’s biggest environmental, social, and governance (ESG) problems such as water pollution, deforestation, and wealth inequality: encourage companies within industries to do less competing... View Details
- 28 May 2008
- First Look
First Look: May 28, 2008
goals? Purchase the case: http://www.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=308030 Can PACIV (Puerto Rico) Serve European Customers? Harvard Business School Case 808-099 Jorge Rodriguez-Gonzalez, PACIV's (Puerto Rico) founding CEO, is considering expanding... View Details
Keywords: Martha Lagace
- 07 Apr 2003
- Research & Ideas
XTV: Xerox’s Attempted Recovery From “Fumbling the Future”
with researchers at PARC. Much of that time was occupied with interviewing prospective customers who had significant problems with document management. For example, a pharmaceutical company that was applying for FDA approval had to manage... View Details
Keywords: by Henry Chesbrough
- 01 Sep 2014
- News
All For One
industries as diverse as automobiles and pharmaceuticals and began to interview and observe them to see how they created environments ripe for innovation. “We didn’t want to just espouse platitudes,” Hill says. “We wanted to tell full... View Details
- March 2017
- Case
Cantel Medical
By: John R. Wells and Gabriel Ellsworth
Cantel Medical Corporation provided infection prevention and control products and services for patients, caregivers, and other healthcare providers. In 2016, Cantel generated sales of $665 million and net profits of $60 million, double the levels of five years earlier.... View Details
Keywords: Cantel; Charles Diker; Furniture Industry; Matrix Organization; Acquisition; Mergers and Acquisitions; Business Conglomerates; Business Units; Business Growth and Maturation; Business Organization; For-Profit Firms; Chemicals; Profit; Revenue; Geographic Scope; Multinational Firms and Management; Health; Health Care and Treatment; Business History; Business or Company Management; Goals and Objectives; Growth and Development Strategy; Organizational Structure; Problems and Challenges; Research and Development; Opportunities; Strategy; Adaptation; Business Strategy; Competitive Strategy; Corporate Strategy; Diversification; Expansion; Information Technology; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States; New Jersey
Wells, John R., and Gabriel Ellsworth. "Cantel Medical." Harvard Business School Case 717-482, March 2017.
- 23 May 2017
- First Look
First Look at New Ideas and Research: May 23, 2017
of one of the top pharmaceutical companies in the world. Vasella, an avowed advocate of diversification, had expanded the scope of the company and structured it into 16 distinct business units ranging from animal health to oncology while... View Details
Keywords: Carmen Nobel
- 01 Jan 2003
- News
Greylock
as Fansteel Metallurgical Corp., Deseret Pharmaceutical Co., New England Nuclear Corp., and Velcro Industries. And by the summer of 1969, it was ready to hire its first associate, Henry McCance, fresh out of three years in defense systems... View Details
- 12 Jan 2016
- First Look
January 12, 2016
November–December 2015 Operations Research Active Postmarketing Drug Surveillance for Multiple Adverse Events By: Goh, Joel, Margrét V. Bjarnadóttir, Mohsen Bayati, and Stefanos A. Zenios Abstract—Postmarketing drug surveillance is the process of monitoring the adverse... View Details
Keywords: Carmen Nobel
- Web
Winners & Success Stories | New Venture Competition
Pharmaceuticals Alec Machiels, MBA 2001 Potentia is a clinical-stage biotechnology company with a world-class scientific team and scientific advisory board. The company’s mission is to bring the first treatment targeting the root cause of... View Details